Антибактериальная терапия при обострении ХОБЛ: что необходимо знать терапевту?

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Last updated 2008. www.goldcopd.org/.
2. Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J 2003; 21 (Suppl. 41): 46s–53s.
3. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000; 117 (5 Suppl. 2): 398S–401S.
4. Stanford RH, Shen Y, McLaughlin T. Cost of chronic obstructive pulmonary disease in the emergency department and hospital: an analysis of administrative data from 218 US hospitals. Treat Respir Med 2006; 5: 343–9.
5. O'Donnell DE, Parker CM. COPD exacerbations: Pathophysiology. Thorax 2006; 61: 354–61.
6. Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847–52.
7. Seemungal TAR, Donaldson GC, Paul EA et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 151: 1418–22.
8. Miravitlles M, Murio C, Guerrero T et al. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 2002; 121: 1449–55.
9. Celli BR, Barnes PJ. Exacerbation of chronic obstructive pulmonary disease. Eur Respir J 2007; 29: 1224–38.
10. Seneff MG, Wagner DP, Wagner RP et al. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA 1995; 274: 1852–7.
11. Zielinski J, MacNee W, Wedzicha J et al. Causes of death in patients with COPD and chronic respiratory failure. Monaldi Arch Chest Dis 1997; 52: 43–7.
12. Veeramachaneni SB, Sethi S. Pathogenesis of bacterial exacerbations of COPD. COPD 2006; 3: 109–15.
13. White AJ, Gompertz S, Stockley RA. Chronic obstructive pulmonary disease. 6: The aetiology of exacerbations of chronic obstructive pulmonary disease. Thorax 2003; 58: 73–80.
14. Monso E, Ruiz J, Rosell A et al. Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 1995; 152: 1316–20.
15. Pela R, Marchesani F, Agostinelli C et al. Airways microbial flora in COPD patients in stable clinical conditions and during exacerbations: a bronchoscopic investigation. Monaldi Arch Chest Dis 1998; 53: 262–7.
16. Sethi S, Evans N, Grant BJB, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002; 347: 465–71.
17. Soler N, Torres A, Ewig S et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med 1998; 157: 1498–505.
18. Fagon JY, Chastre J, Trouillet JL et al. Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis. Use of the pro tected specimen brush technique in 54 mechanically ventilated patients. Am Rev Respir Dis 1990; 142: 1004–8.
19. Miravitlles M, Espinosa C, Fernandez Laso E et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest 1999; 116: 40–6.
20. Eller J, Ede A, Schaberg T et al. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest 1998; 113: 1542–8.
21. von Hertzen L, Isoaho R, Leinonen M et al. Chlamydia pneumoniae antibodies in chronic obstructive pulmonary disease. Int J Epidemiol 1996; 25: 658–64.
22. Mogulkoc N, Karakurt S, Isalska B et al. Acute purulent exacerbation of chronic obstructive pulmonary disease and Chlamydia pneumoniae infection. Am J Respir Crit Care Med 1999; 160: 349–53.
23. Diederen BM, van der Valk PD, Kluytmans JA et al. The role of atypical respiratory pathogens in exacerbations of chronic obstructive pulmonary disease. Eur Respir J 2007; 30: 240–4.
24. Ball P, Harris JM, Lowson D et al. Acute infective exacerbations of chronic bronchitis. Q J Med 1995; 88: 61–8.
25. Papi A et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006; 173 (10): 1114–21.
26. Seemungal T, Donaldson GC, Breuer J et al. Rhinoviruses are associated with exacerbations of COPD. Eur Respir J 1998; 12 (Suppl. 28): 298s.
27. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 2355–65.
28. Hirschmann JV. Do bacteria cause exacerbations of COPD? Chest 2000; 118: 193–203.
29. Sachs APE, Koeter GH, Groenier KH et al. Changes in symptoms, peak expiratory flow, and sputum flora during treatment with antibiotics of exacerbations in patients with chronic obstructive pulmonary disease in general practice. Thorax 1995; 50: 758–63.
30. Puhan MA, Vollenweider D, Latshang T et al. Exacerbations of chronic obstructive pulmonary disease: when are antibiotics indicated? A systematic review. Respir Res 2007; 8: 30.
31. Anthonisen NR, Manfreda J, Warren CPW et al. Antibiotic therapy in acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196–204.
32. Nouira S, Marghli S, Belghith M et al. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbations requiring mechanical ventilation: a randomised placebo-controlled trial. Lancet 2001; 358: 2020–5.
33. Wilson R, Allegra L, Huchon G et al. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 2004; 125: 953–64.
34. Chodosh S. Clinical significance of the infection-free interval in the management of acute bacterial exacerbations of chronic bronchitis. Chest 2005; 127: 2231–6.
35. Adams S, Melo J, Luther M et al. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of chronic obstructive pulmonary disease. Chest 2000; 117: 1345–52.
36. Roede BM, Bresser P, Prins JM et al. Reduced risk of next exacerbation and mortality associated with antibiotic use in COPD. Eur Respir J 2009; 33: 282–8.
37. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932–46.
38. Stockley RA, O'Brien C, Pye A, Hill SL. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000; 117: 1638–45.
39. Soler N, Agusti C, Angrill J et al. Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease. Thorax 2007; 62: 29–35.
40. Nseir S, Ader F. Prevalence and outcome of severe chronic obstructive pulmonary disease exacerbations caused by multidrug-resistant bacteria. Curr Opin Pulm Med 2008; 14: 95–100.
41. Lacoma A, Prat C, Andreo F, Dominguez J. Biomarkers in the management of COPD. Eur Respir Rev 2009; 18 (112): 96–104.
42. Christ-Crain M, Muller B. Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur Respir J 2007; 30: 556–73.
43. Nylen ES, Snider RH, Thompson KA et al. Pneumonitis-associated hyperprocalcitoninemia. Am J Med Sci 1996; 312: 12–8.
44. Boussekey N, Leroy O, Alfandari S et al. Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia. Intensive Care Med 2006; 32: 469–72.
45. Becker KL, Nylen ES, White JC, Muller B, Snider RH Jr. Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab 2004; 89: 1512–25.
46. Stolz D, Christ-Crain M, Bingisser R et al. Antibiotic treatment of exacerbations of COPD. A randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007; 131: 9–19.
47. Pepys MB, Berger A. The renaissance of C reactive protein. BMJ 2001; 322: 4–5.
48. Kolb-Bachofen V. A review on the biological properties of C-reactive protein. Immunobiology 1991; 183: 133–45.
49. Ballou SP, Kushner I. C-reactive protein and the acute phase response. Adv Intern Med 1992; 37: 313–36.
50. Gewurz H, Zhang X, Lint T. Structure and function of the pentraxins. Curr Opin Immunol 1995; 7: 54–64.
51. Shine B, de Beer FC, Pepys MB. Solid phase radioimmunoassays for human Creactive protein. Clin Chim Acta 1981; 117: 13–23.
52. Hutchinson WL et al. Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population. Clin Chem 2000; 46: 934–8.
53. Hurst JR, Donaldson GC, Perera WR. Use of Plasma Biomarkers at Exacerbation of Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2006; 174: 867–74.
54. Dev D, Sankaran EWR, Cunnife J et al. Value of C-reactive protein in exacerbation of chronic obstructive pulmonary disease. Respir Med 1998; 92: 664–7.
55. Baimakanova G, Zubairova P, Avdeev S, Chuchalin A. Performance of rapid, bedside whole blood C-reactive protein (CRP) test as a diagnostic test for bacterial infection and pneumonia in patients with acute exacerbation of chronic obstructive pulmonary disease. Eur Respir J 2007; 29 (Suppl.): 556s.
56. Авдеев С.Н., Баймаканова Г.Е., Зубаирова П.А. Возможности С-реактивного белка в диагностике бактериальной инфекции и пневмонии у больных с обострением хронической обструктивной болезни легких. Урал. мед. журн. 2008; 13: 19–24.
57. Martinez FJ, Han MK, Flaherty K, Curtis J. Role of infection and antimicrobial therapy in acute exacerbations of chronic obstructive pulmonary disease. Expert Rev Antiinfect Ther 2006; 4: 101–24.
58. Ram FS, Rodriguez-Roisin R, Granados-Navarrete A et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev (database online). Issue 2, 2006.
59. Grossman RF. Guidelines for the treatment of acute exacerbations of chronic bronchitis. Chest 1997; 112 (suppl.): 310S–3S.
60. Wilson R, Jones P, Schaberg T et al. Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitis. Thorax 2006; 61: 337–42.
61. Dimopoulos G, Siempos II, Korbila IP et al. Comparison of first-line with second-line antibiotics for acute exacerbations of chronic bronchitis: a metaanalysis of randomized controlled trials. Chest 2007; 132: 447–55.
62. Siempos II, Dimopoulos G, Korbila IP et al. Macrolides, quinolones and amoxicillin/clavulanate for chronic bronchitis: a meta-analysis. Eur Respir J 2007; 29: 1127–37.
63. Contopoulos-loannidis DG, Ioannidis JPA, Chewc P, Law J. Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for lower respiratory tract infections. J Antimicrob Chemother 2001; 48: 691–703.
64. Meyler's side effects of drugs. 13-th ed. Ed. Dukes MNG. Elsevier Science 1996; 693–744.
65. Козлов Р.С., Сивая О.В., Шпынев К.В. и др. Антибиотикорезистентность Streptococcus pneumoniae в России в 1999–2005 гг.: результаты многоцентровых проспективных исследований ПеГАС-I и ПеГАС-II. Клин. микробиол. антимикроб. химиотер. 2006; 8: 33–47.
66. Hoepelman IM, Mollers MJ, van Schie MH et al. A short (3-day) course of azithromycin tablets versus a 10-day course of amoxycillin-clavulanic acid (co-amoxiclav) in the treatment of adults with lower respiratory tract infections and effects on long-term outcome. Int J Antimicrob Agents 1998; 9: 141–6.
67. Anzueto A, Fisher CLJr, Busman T, Olson CA. Comparison of the efficacy of extended-release clarithromycin tablets and amoxicillin/clavulanate tablets in the treatment of acute exacerbation of chronic bronchitis. Clin Ther 2001; 23: 72–86.
68. Castaldo RS, Celli BR, Gomez F et al. A comparison of 5-day courses of dirithromycin and azithromycin in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Clin Ther 2003; 25: 542–57.
69. Amsden GW, Baird IM, Simon S, Treadway G. Efficacy and safety of azithromycin versus levofloxacin in the outpatient treatment of acute bacterial exacerbations of chronic bronchitis. Chest 2003; 123: 772–7.
70. Andre-Alves MR, Jardim JR, Silva RF et al. Comparison between azithromycin and amoxicillin in the treatment of infectious exacerbation of chronic obstructive pulmonary disease. J Bras Pneumol 2007; 33: 43–50.
71. Rubin BK. Immunomodulatory properties of macrolides: overview and historical perspective. Amer J Med 2004; 117 (9A): 2S–4S.
72. EUCAST Expert rules in antimicrobial susceptibility testing, version 1, April 2008. http://www.EUCAST.org.
73. O'Donnell JA, Gelone SP. The newer fluoroquinolones. Infect Dis Clin N Am 2004; 18: 691–716.
74. Blasi F, Tarsia P, Aliberti S et al. Highlights on the appropriate use of fluoroquinolones in respiratory tract infections. Pulm Pharmacol Therap 2006; 19: 11–9.
75. Bonfiglio G. Is levofloxacin as active as ciprofloxacin against Pseudomonas aeruginosa? Chemotherapy 2001; 47: 239–42.
76. Антибиотикорезистентность в России: Возбудители внебольничных инфекций. Available on http://www.antibiotic.ru.
77. Societe de Pathologie Infectieuse de Langue Fran_aise: 15th consensus conference about management of lower respiratory tract infections in immunocompetent adult. Med Mal Infect 2006; 36: 235–44.
78. Сидоренко С.В., Козлов С.Н. Группа пенициллинов. Практическое руководство по антиинфекционной химиотерапии. Под ред. Л.С.Страчунского, Ю.Б.Белоусова, С.Н.Козлова. М., 2002; с. 47–55.
79. Дворецкий Л.И., Дубровская Н.В., Грудинина С.А. и др. Клинико-микробиологический мониторинг больных с обострением хронического бронхита, леченных антибактериальными препаратами. Тер. арх. 2006; 78 (3): 25–35.
80. Neu HC, Wilson, APR. Gruneberg RN. Amoxycillin/clavulanic acid: a review of its efficacy in over 38,500 patients from 1979 to 1992. J Chemother 1993; 5: 67–93.
81. Карпов О.И. Флемоклав Солютаб – новая лекарственная форма амоксициллина/клавуланата в лечении синусита. Клиническая фармакология и терапия. 2006; 15 (4): 1–4.
82. Cortvriendt WR, Verschoor JS, Hespe W. Bioavailability study of a new amoxicillin tablet designed for several modes of oral administration. Arzneimittelforschung 1987; 37: 977–9.
83. Sourgens H, Steinbrede H, Verschoor JS et al. Bioequivalence study of a novel Solutab tablet formulation of amoxicillin/clavulanic acid versus the originator film-coated tablet. Int J Clin Pharmacol Ther 2001; 39: 75–82.
84. Гучев И.А., Козлов Р.С. Безопасность и эффективность различных лекарственных форм Амоксициллина/клавулановой кислоты при инфекциях нижних дыхательных путей у взрослых: Открытое проспективное рандомизированное исследование. Пульмонология. 2008; 2: 73–80.
85. Sethi S, Breton J, Wynne B. Efficacy and safety of pharmacokinetically enhanced amoxicillin-clavulanate at 2,000/125 milligrams twice daily for 5 days versus amoxicillin-clavulanate at 875/125 milligrams twice daily for 7 days in the treatment of acute exacerbations of chronic bronchitis. Antimicrob Agents Chemother 2005; 49: 153–60.
86. Alvarez-Sala JL, Kardos P, Martinez-Beltran J et al. Clinical and bacteriological efficacy in treatment of acute exacerbations of chronic bronchitis with cefditoren-pivoxil versus cefuroxime-axetil. Antimicrob Agents Chemother 2006; 50: 1762–7.
87. Chodosh S, DeAbate CA, Haverstock D et al. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. Respir Med 2000; 94: 18–27.
88. Wilson R, Schentag JJ, Ball P, Mandell L. for the 068 Study Group. A comparison of Gemifloxacin and Clarithromycin in Acute Exacerbations of Chronic Bronchitis and Long-term clinical outcomes. Clin Ther 2002; 4: 639–52.
89. Sethi S, Fogarty C, Fulambarker A. A randomized, double-blind study comparing 5 days oral gemifloxacin with 7 days oral levofloxacin in patients with acute exacerbation of chronic bronchitis. Respir Med 2004; 98: 697–707.
90. Fogarty C, De Wet R, Mandell L et al. Five-day telithromycin once daily is as effective as 10-day clarithromycin twice daily for the treatment of acute exacerbations of chronic bronchitis and is associated with reduced health-care resource utilization. Chest 2005; 128: 1980–8.
91. Guay DRP. Short-course antimicrobial therapy of respiratory tract infections. Drugs 2003; 63: 2169–84.
92. Kardas R. Patient compliance with antibiotic treatment for respiratory tract infections. J Antimicrob Chemother 2002; 49: 897–903. Falagas ME, Avgeri SG, Matthaiou DK et al. Short-versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis: a meta-analysis. J Antimicrob Chemother 2008; 62: 442–50.
93. El Moussaoui R, Roede BM, Speelman P et al. Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies. Thorax 2008; 63: 415–22.
94. Roede BM, Bresser P, El Moussaoui R et al. Three vs. 10 days of amoxycillin–clavulanic acid for type 1 acute exacerbations of chronic obstructive pulmonary disease: a randomised, double-blind study. Clin Microbiol Infect 2007; 13: 284–90.
95. Christ-Crain M, Stolz D, Bingisser R et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006; 174: 84–93.
96. Nobre V, Harbarth S, Graf J-D et al. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: A randomized trial. Am J Respir Crit Care Med 2008; 177: 498–505.